Table 1.

Study characteristics.

Study	Year	Patient (n)		DAPT (months)	Follow-Up (months)	Anti-Proliferative Drug		Outcomes
		PF-DES	DP-DES			PF-DES	DP-DES
BioFreedom FIM [19]	2016	122	60	6	60	Biolimus	Paclitaxel	Definite or probable ST, MI, cardiac death, all-cause death, TLR, TVR
Dang [20]	2012	50	55	6	12	Paclitaxel	Sirolimus	Definite or probable ST, MI, cardiac death, all-cause death, TLR
ISAR-TEST [21]	2013	225	225	6	60	Sirolimus	Paclitaxel	Definite or probable ST, MI, cardiac death, all-cause death, TLR
ISAR-TEST-2 [16]	2010	333	335	12	24	Sirolimus/Probucol	Sirolimus	Definite or probable ST, MI, all-cause death
ISAR-TEST-3 [17]	2009	201	202	12	24	Sirolimus	Sirolimus	Definite or probable ST, MI, all-cause death, TLR
ISAR-TEST-5 [22]	2016	2002	1000	6	60	Sirolimus/Probucol	Zotarolimus	Definite or probable ST, MI, cardiac death, all-cause death, TLR, TVR
LIPSIA Yukon [26]	2014	118	114	12	60	Sirolimus	Paclitaxel	Definite or probable ST, MI, cardiac death, all-cause death, TLR, TVR
Nano [27]	2014	132	136	12	24	Sirolimus	Sirolimus	Definite or probable ST, MI, cardiac death, all-cause death, TVR
NEXT [18]	2012	148	148	6	12	Amphilimus	Paclitaxel	Definite or probable ST, MI, cardiac death, all-cause death, TLR, TVR
ReCre8 [24]	2018	747	744	12	12	Amphilimus	Zotarolimus	Definite or probable ST, MI, cardiac death, all-cause death, TLR
RESERVOIR [23]	2016	56	56	12	12	Amphilimus	Everolimus	MI, cardiac death
Shiratori [25]	2014	84	80	6	24	Paclitaxel	Paclitaxel	Definite or probable ST, MI, cardiac death, all-cause death, TLR, TVR
Zhang [28]	2013	327	321	12	24	Paclitaxel	Sirolimus	Definite or probable ST, MI, cardiac death, all-cause death, TVR

DAPT = dual antiplatelet therapy; DP-DES = durable polymer drug-eluting stents; MI = myocardial infarction; PF-DES = polymer-free drug-eluting stents; ST = stent thrombosis; TLR = target lesion revascularization; TVR = target vessel revascularization.